Get the Stockscreener App
0.7534
5.36%
-0.0427
After Hours:
.75
-0.0034
-0.45%
Psyence Biomedical Ltd stock is traded at $0.7534, with a volume of 552.91K.
It is down -5.36% in the last 24 hours and down -50.92% over the past month.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
See More
Previous Close:
$0.7961
Open:
$0.82
24h Volume:
552.91K
Relative Volume:
0.43
Market Cap:
$1.41M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-15.35%
1M Performance:
-50.92%
6M Performance:
-85.86%
1Y Performance:
-95.52%
1-Day Range:
$0.662
$0.82
1-Week Range:
$0.662
$0.9464
52-Week Range:
$0.662
$18.09
Psyence Biomedical Ltd Stock (PBM) Company Profile
Compare PBM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBM
Psyence Biomedical Ltd
|
0.7534 | 1.49M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Psyence Biomedical Ltd Stock (PBM) Latest News
Gainers Report: Why Psyence Biomedical Ltd stock could benefit from AI revolutionSell Signal & Real-Time Chart Pattern Alerts - moha.gov.vn
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing - TMX Newsfile
Psyence Biomedical (NASDAQ:PBM) Trading Down 6.1% – Here’s Why - Defense World
How Psyence Biomedical Ltd. stock performs in weak economyJuly 2025 Price Swings & Weekly Chart Analysis and Trade Guides - Улправда
Published on: 2025-12-20 18:04:24 - Улправда
Will Psyence Biomedical Ltd. stock benefit from upcoming earnings reportsJuly 2025 Decliners & Technical Buy Zone Confirmations - Улправда
Investment Review: Is Psyence Biomedical Ltd. stock attractive for hedge fundsDay Trade & Safe Capital Growth Plans - moha.gov.vn
Psyence Biomedical’s psilocybin approved for Phase IIb trial use By Investing.com - Investing.com Nigeria
{Company Name} Stock Soars on Exciting Developments - StocksToTrade
Psyence Biomedical stock rises after ethics approval for psilocybin trial By Investing.com - Investing.com South Africa
Psyence Biomedical stock rises after ethics approval for psilocybin trial - Investing.com India
Psyence Biomedical Ltd. Announces Approval for Use of Psylabs' Psilocybin Product in Phase IIb Clinical Trial - marketscreener.com
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial - The Manila Times
Psyence BioMed announces approval for use of Psylabs' psilocybin product in phase IIb clinical trial - marketscreener.com
Psyence Biomedical’s psilocybin approved for Phase IIb trial use - Investing.com
Psyence BioMed Announces Approval For Use Of Psylabs’ Psilocybin Product In Phase IIb Clinical Trial - TradingView — Track All Markets
Psychedelic therapy trial for patients with cancer moves forward in Australia - Stock Titan
Will Psyence Biomedical Ltd. Equity Warrant stock gain from government policies2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Can Psyence Biomedical Ltd. stock rebound after recent weakness2025 Risk Factors & Weekly Top Performers Watchlists - DonanımHaber
New Highs: Will Psyence Biomedical Ltd. stock benefit from upcoming earnings reportsForecast Cut & Real-Time Sentiment Analysis - Улправда
Will Psyence Biomedical Ltd. stock beat EPS estimatesPortfolio Performance Report & Low Risk Entry Point Tips - ulpravda.ru
Why Psyence Biomedical Ltd. Equity Warrant stock is popular among millennialsWeekly Gains Report & Fast Gaining Stock Strategy Reports - Улправда
Is Psyence Biomedical Ltd. Equity Warrant stock dividend yield sustainableJuly 2025 Selloffs & Weekly Consistent Profit Watchlists - Улправда
Why Psyence Biomedical Ltd. Equity Warrant stock remains a top recommendation2025 Bull vs Bear & Low Risk High Reward Trade Ideas - Улправда
How geopolitical tensions affect Psyence Biomedical Ltd. stock2025 Trading Recap & AI Powered Trade Plan Recommendations - Улправда
Psyence Biomedical Ltd. (PBM) -5.7% in After-hours: Despite No Clear Catalyst - Stocks Telegraph
Psyence BioMed Advances Phase IIb Clinical Trial and Expands Board - MSN
Check out these key findings about Psyence Biomedical Ltd (PBM) - setenews.com
Rapid Surge: Psyence Biomedical’s Unexpected Stock Movement - StocksToTrade
Psyence BioMed (PBM) Stock: Drives Forward with Phase IIb Trial and Unique Longevity Science Position - parameter.io
Psyence Biomedical Ltd. (PBM) Stock: Drops, But Company Pushes Forward with Groundbreaking Psychedelic Therapies - parameter.io
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science - Asianet Newsable
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science - The Manila Times
Bull Run: Why Psyence Biomedical Ltd stock appeals to dividend seekersTrade Performance Summary & Long-Term Growth Portfolio Plans - moha.gov.vn
How Psyence Biomedical Ltd. Equity Warrant stock benefits from global expansionJuly 2025 Market Mood & Reliable Entry Point Alerts - Newser
Will Psyence Biomedical Ltd. Equity Warrant stock remain a Wall Street favoriteWeekly Gains Report & Reliable Volume Spike Trade Alerts - Newser
Will Psyence Biomedical Ltd. Equity Warrant stock sustain high P E ratiosAnalyst Downgrade & Safe Entry Trade Signal Reports - Newser
Is Psyence Biomedical Ltd. stock attractive for growth ETFsPortfolio Risk Report & Reliable Entry Point Trade Alerts - Newser
Price to earnings ratio of Psyence Biomedical Ltd. Warrant 20242028 on Psyence Biomedical – NASDAQ:PBMWW - TradingView
Psyence Biomedical (PBM) Stock Analysis Report | Financials & Insights - Benzinga
Psyence Biomedical (NASDAQ:PBM) Trading Down 2.5% – Should You Sell? - Defense World
Psyence Biomedical Ltd. (PBM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Psyence Biomedical : The Future of Human Longevity Will Be Transformational – And Nature May Hold the Key - marketscreener.com
Psyence BioMed leads longevity research on psilocybin - Longevity.Technology
Its Stock Has Paid Off Big Time For Psyence Biomedical Ltd - Setenews
Breakout Move: Why Psyence Biomedical Ltd. Equity Warrant stock is popular among millennialsEntry Point & Safe Capital Growth Stock Tips - moha.gov.vn
Psyence Biomedical launches psilocybin longevity research program By Investing.com - Investing.com Nigeria
Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program - Asianet Newsable
Psyence Biomedical launches psilocybin longevity research program - Investing.com
Psyence Biomedical Ltd Stock (PBM) Financials Data
There is no financial data for Psyence Biomedical Ltd (PBM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):